Answers are grounded in this paper and cite their sources.
febrile UTI randomized to prophylaxis with trimethoprim/sulfamethoxazole (TMP/SMZ), or placebo and followed over a study timeline for 2 years. Overall, a 50% reduction was noted in the incidence of recurrent febrile UTI with the utilization of prophylaxis as compared to placebo. Additional sub-group analyses have been performed on the cohorts of the study; these are also evaluated in this review to determine the overall impact of the RiVUR study on the current management of VUR.
No takes yet. Share an insight, caveat, or question.
Damm et al. (2022) studied this question.
Synapse has enriched 3 related papers. Consider them for comparative context: